 | • レポートコード：MRC2303M141 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料によると、世界の小児用呼吸器疾患治療薬市場規模が、予測期間中に年平均成長率5.6%で拡大すると予測されています。本書は、小児用呼吸器疾患治療薬の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療薬別（抗炎症薬、気管支拡張薬、配合剤、コルチコステロイド、その他）分析、疾患別（喘息、嚢胞性線維症、細気管支炎、肺炎、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などが掲載されています。また、F. Hoffmann-La Roche AG (Genentech, Inc.)、Novartis AG、Bayer AG、GlaxoSmithKline plc、Merck & Co、Boehringer Ingelheim GmbH、Regeneron Pharmaceuticals、AstraZeneca plc、Vertex Pharmaceuticals Incorporated、Johnson & Johnsonなど、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の小児用呼吸器疾患治療薬市場規模：治療薬別 - 抗炎症薬の市場規模 - 気管支拡張薬の市場規模 - 配合剤の市場規模 - コルチコステロイドの市場規模 - その他の市場規模 ・世界の小児用呼吸器疾患治療薬市場規模：疾患別 - 喘息の市場規模 - 嚢胞性線維症の市場規模 - 細気管支炎の市場規模 - 肺炎の市場規模 - その他の市場規模 ・世界の小児用呼吸器疾患治療薬市場規模：地域別 - 北米の小児用呼吸器疾患治療薬市場規模 アメリカの小児用呼吸器疾患治療薬市場規模 カナダの小児用呼吸器疾患治療薬市場規模 メキシコの小児用呼吸器疾患治療薬市場規模 … - ヨーロッパの小児用呼吸器疾患治療薬市場規模 イギリスの小児用呼吸器疾患治療薬市場規模 フランスの小児用呼吸器疾患治療薬市場規模 ドイツの小児用呼吸器疾患治療薬市場規模 … - アジア太平洋の小児用呼吸器疾患治療薬市場規模 中国の小児用呼吸器疾患治療薬市場規模 インドの小児用呼吸器疾患治療薬市場規模 日本の小児用呼吸器疾患治療薬市場規模 … - 南米/中東の小児用呼吸器疾患治療薬市場規模 ブラジルの小児用呼吸器疾患治療薬市場規模 アルゼンチンの小児用呼吸器疾患治療薬市場規模 南アフリカの小児用呼吸器疾患治療薬市場規模 … - その他地域の小児用呼吸器疾患治療薬市場規模 ・競争状況 ・市場機会・将来の動向 |
The pediatric respiratory disease therapeutics market is expected to register a CAGR of 5.6% over the forecast period.
The pandemic significantly impacted the pediatric respiratory disease therapeutics market as the demand for pediatric respiratory disease therapeutics products increased owing to the increased risk of respiratory illness. For instance, as per a study published by the NCBI in September 2022, low-field magnetic MRI showed persistent pulmonary dysfunction in both children and adolescents who recovered from COVID-19 and with long COVID. Similarly, per the study published by the IJP in November 2021, the pandemic has brought significant challenges to childcare worldwide. Respiratory disease therapeutics such as anti-inflammatory drugs, bronchodilators, and combination drugs are generally used for the treatment of various respiratory diseases. Thus, the increasing incidence of respiratory diseases among pediatrics and continuous treatment during the pandemic helped the market to maintain considerable growth. With the emergence of the new strain, the market is expected to move upward over the forecast period.
The increasing prevalence of chronic respiratory diseases and increasing research and development in drug discovery for respiratory diseases are the major drivers for the market. For instance, as per the report published by the WHO in October 2022, an estimated 10.6 million people suffered from tuberculosis (TB) in 2021 globally of which 1.2 million were children. The report also stated that TB is prevalent in all countries and age groups. In addition, the burden of asthma and allergic diseases continues to increase among pediatrics. Moreover, every year pediatric respiratory infections impose a significant burden on the global healthcare system in terms of manpower and resource utilization.
Furthermore, as per the October 2021 CDC report, there were more than 317 cases of tuberculosis disease among children aged 14 years or younger in the United States, accounting for 4.0% of all people reported with tuberculosis nationally in 2021. According to UNICEF data published in August 2022, there were more than 1,400 cases of pneumonia per 100,000 children, or 1 case in 71 children each year, globally, with the highest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children).
The increasing research and development in drug discovery is also another driving factor for the market. For instance, as per the journal published by the Frontiers Organization in October 2021, research is being conducted to identify prognostic respiratory disorder/disease progression-specific biomarkers that can predict disease course in children and to develop scoring and risk stratification systems. Similarly, in September 2021, Children’s National Hospital received USD 2.13 million in awards from the National Institutes of Health’s (NIH) National Heart, Lung and Blood Institute to accelerate research work and develop new diagnostic tools and innovative precision medicine related to treatments for kids with down syndrome experiencing respiratory viruses. It is expected that such advancements may create new opportunities for the market and may encourage new players to enter the market.
Pediatric Respiratory Disease Therapeutics Market Trends
The Asthma Segment is Expected to Witness Considerable Growth Over the Forecast Period
Asthma is the most common chronic respiratory disease affecting children globally. Asthma is a chronic (long-term) condition that affects the airways in the lungs. The airways of asthma patients can sometimes become inflamed and narrow. This makes it difficult for air to flow out of the airways when exhaling. Asthma is a major non-communicable disease (NCD) and can also affect adults.
The increasing number of pediatric asthma cases is one of the major drivers for the segment’s growth. For instance, per the journal published by the ERJ open research in August 2022, a study based on the ISAAC questionnaire reported a prevalence rate of bronchial asthma of 13.1% in children aged 11 to 16 across the globe. Similarly, per the report published by the CDC in May 2022, 1 in 12, about 6.0 million children in the United States aged 0-17 years, suffer from asthma every year. Such instances indicate that the demand for asthma drugs and therapeutics is anticipated to increase, propelling segment growth.
The new product launch and approvals of drugs for treating asthma in children are also anticipated to propel the segment growth. For instance, in October 2021, the United States Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance treatment for patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Similarly, in December 2021, AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) has been approved in the United States for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is expected to dominate the overall pediatric respiratory disease therapeutics market over the forecast period. The factors driving the market are increasing cases of pediatric respiratory diseases, increasing research work, and continuous product launches and approvals. According to a report published by Asthma Canada in June 2021, more than 850,000 children under the age of 14 have asthma, making it the most common chronic disease among children and the leading cause of both school absenteeism and hospitalization in Canada. Similarly, as per the journal published by the CMAJ Group in May 2021, asthma is the most common chronic disease in children, with a prevalence of 15.0% to 25.0% in Canada.
Key product launches, high concentration of market players or manufacturer’s presence, acquisition and partnerships among major players, and increasing cases of respiratory diseases and research works and clinical trials in the United States are some of the factors driving the growth of the pediatric respiratory disease therapeutics market in the country. For instance, in April 2021, Sanofi’s Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in the Phase 3 trial.
Pediatric Respiratory Disease Therapeutics Market Competitor Analysis
The pediatric respiratory disease therapeutics market is moderately competitive due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well-known including Novartis AG, Bayer AG, GlaxoSmithKline plc, Merck & Co, Boehringer Ingelheim GmbH, AstraZeneca plc among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Defination
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Respiratory Diseases
4.2.2 Increasing Research and Development in Drug Discovery for Respiratory Diseases
4.3 Market Restraints
4.3.1 Stringent Regulations for Drug Approval
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Drug Class
5.1.1 Anti-Inflammatory Drugs
5.1.2 Bronchodilators
5.1.3 Combination Drugs
5.1.4 Corticosteroid
5.1.5 Monoclonal Antibodies
5.1.6 Other Drug Classes
5.2 By Disease
5.2.1 Asthma
5.2.2 Cystic Fibrosis
5.2.3 Bronchiolitis
5.2.4 Pneumonia
5.2.5 Tuberculosis
5.2.6 Other Diseases
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche AG (Genentech, Inc.)
6.1.2 Novartis AG
6.1.3 Bayer AG
6.1.4 GlaxoSmithKline plc
6.1.5 Merck & Co
6.1.6 Boehringer Ingelheim GmbH
6.1.7 Regeneron Pharmaceuticals
6.1.8 AstraZeneca plc
6.1.9 Vertex Pharmaceuticals Incorporated
6.1.10 Johnson & Johnson
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
